



## Correction Number 1 Made to the List of Medications

An Act respecting prescription drug insurance  
(chapter A-29.01, s. 60, 7th par. 7 and s. 60.2)

In accordance with section 60.2 of the Act respecting prescription drug insurance, the Régie de l'assurance maladie du Québec has been notified of the reduction in the price of several medications. Consequently, the Régie has made the necessary corrections to the List of Medications attached to the Regulation respecting the List of medications covered by the basic prescription drug insurance plan published on 20 March 2017 on the website of the Régie and in force on 22 March 2017.

These corrections are aimed at reducing the price of medications pursuant to the regulatory commitment by manufacturers, which provides that a manufacturer must submit to Québec a selling price that does not exceed “any selling price granted by the manufacturer for the same drug under other provincial drug insurance programs” (best Canadian price). In this regard, the pan-Canadian Pharmaceutical Alliance published the name of six molecules for which the current price point of 18% of the price of the brand-name medication will be reduced to 15% as of 1 April 2017. The molecules in question are atorvastatin calcium, amlodipine besylate, simvastatin, pantoprazole magnesium or sodium, ramipril and clopidogrel bisulfate. In order for Québec to benefit from this price reduction, the Régie must make a correction, to have effect from 1 April 2017.

Secondly, the Régie has been notified by the manufacturers Merck and Aspen of the reduction in the price of the following medications, and a price correction is therefore necessary:

Code	Brand name	Manufacturer	Packaging size	Cost of package size indicated	Corrected cost of package size	Unit price indicated	Corrected unit price
02451131	Zepatier	Merck	28	20100.00	18674.32	717.8571	666.94
02258056	Arixtra	Aspen	1	25.00	17.50	n/a	n/a

Thirdly, a mismatch has been observed in the price established in the registration agreement between the manufacturer and the MSSS and the price indicated on the List of Medications of 22 March 2017 with regard to the following medications, and a correction is therefore necessary:

Code	Brand name	Manufacturer	Packaging size	Cost of package size indicated	Corrected cost of package size	Unit price indicated	Corrected unit price
02426862	Aptiom	Sunovion	30	255.00	286.80	8.50	9.56
02426870	Aptiom	Sunovion	30	255.00	286.80	8.50	9.56
02426889	Aptiom	Sunovion	60	510.00	573.60	8.50	9.56
02426897	Aptiom	Sunovion	30	255.00	286.80	8.50	9.56

Finally, it has been observed that the following product should not have been entered on the List of Medications of 22 March 2017 in keeping with the registration agreement between the manufacturer and the MSSS, and its removal is therefore necessary:

Code	Brand name	Manufacturer	Packaging size	Cost of package size
02260565	Xolair	Novartis	1	612.00

These corrections have effect from 1 April 2017.

Publication of this correction on the website of the Régie imparts authentic value to it, in accordance with the last paragraph of section 60 of the Act respecting prescription drug insurance.

Québec, 30 March 2017

Original signed by

Chantal Garcia  
Secretary General of the  
Régie de l'assurance maladie du Québec